ST3GAL2: A Potential Drug Target for Neuro Psychiatric Conditions

Target Name: ST3GAL2

NCBI ID: G6483

ST3GAL2

ST3GAL2: A Potential Drug Target for Neuro Psychiatric Conditions

ST3GAL2, also known as ST3GalII, is a protein that is expressed in many different tissues throughout the body. It is a member of the ST3 family of cytoskeletal proteins, which are involved in the structure and function of cells. ST3GAL2 is unique because it is a type of cytoskeleton that is expressed in the brain, making it a potential drug target for a variety of neurological and psychiatric conditions.

The ST3 family of cytoskeletal proteins is characterized by the presence of a unique protein called tyrosine-protein kinase (TPK) domains. These domains are responsible for the regulation of a variety of cellular processes, including cell growth, differentiation, and survival. ST3GAL2 is a member of the ST3 family because it contains a TPK domain that is similar to those found in other members of the ST3 family.

One of the unique features of ST3GAL2 is its expression in the brain. The brain is a highly controlled organ that is responsible for the majority of a person's thoughts, emotions, and behaviors. As a result, conditions that affect the brain, such as Alzheimer's disease, Parkinson's disease, and other neuro psychiatric disorders, are often treated with drugs that aim to correct or prevent the misfolding of proteins. Misfolded proteins, such as those found in Alzheimer's disease, can cause a build-up of toxic tangles in the brain, leading to the devastating symptoms associated with the disease.

ST3GAL2 has the potential to be a drug target for a variety of neuro psychiatric conditions because of its expression in the brain and its involvement in the regulation of cellular processes that are important in the development and progression of these conditions. For example, studies have shown that misfolded proteins, such as those found in Alzheimer's disease, are prevalent in the brain and that ST3GAL2 plays a role in their regulation. Additionally, ST3GAL2 has been shown to be involved in the regulation of brain size and in the development of neuro-fibrillary tangles, which are a hallmark of Alzheimer's disease.

Another potential drug target for ST3GAL2 is its role in the regulation of cell survival. Cell death, or apoptosis, is a natural process that is important for the development and maintenance of tissues and organs. However, in the case of neuro psychiatric conditions, abnormal cell death can contribute to the development and progression of these conditions.

ST3GAL2 has been shown to play a role in the regulation of cell survival by promoting the survival of neuronal cells. This is done through its ability to interact with a protein called p53, which is a well-known regulator of apoptosis. p53 is a protein that is often activated in response to DNA damage or other stressors, and it plays a role in the regulation of cell survival by promoting the production of pro-inflammatory cytokines and activating caspases that can cause cell death.

In conclusion, ST3GAL2 is a protein that is expressed in many different tissues throughout the body and has the potential to be a drug target for a variety of neuro psychiatric conditions. Its unique expression in the brain and its involvement in the regulation of cellular processes that are important in the development and progression of these conditions make it an attractive target for drug development. Further research is needed to fully understand the role of ST3GAL2 in the regulation of cellular processes and its potential as a drug target.

Protein Name: ST3 Beta-galactoside Alpha-2,3-sialyltransferase 2

Functions: A beta-galactoside alpha2-3 sialyltransferase primarily involved in terminal sialylation of ganglio and globo series glycolipids (PubMed:8920913, PubMed:9266697). Catalyzes the transfer of sialic acid (N-acetyl-neuraminic acid; Neu5Ac) from the nucleotide sugar donor CMP-Neu5Ac onto acceptor Galbeta-(1->3)-GalNAc-terminated glycoconjugates through an alpha2-3 linkage (PubMed:8920913, PubMed:9266697, PubMed:25916169). Sialylates GM1/GM1a, GA1/asialo-GM1 and GD1b gangliosides to form GD1a, GM1b and GT1b, respectively (PubMed:8920913, PubMed:9266697). Together with ST3GAL3, primarily responsible for biosynthesis of brain GD1a and GT1b that function as ligands for myelin-associated glycoprotein MAG on axons, regulating MAG expression and axonal myelin stability and regeneration (By similarity). Via GT1b regulates TLR2 signaling in spinal cord microglia in response to nerve injury (By similarity). Responsible for the sialylation of the pluripotent stem cell- and cancer stem cell-associated antigen SSEA3, forming SSEA4 (PubMed:12716912). Sialylates with low efficiency asialofetuin, presumably onto O-glycosidically linked Galbeta-(1->3)-GalNAc-O-Ser (PubMed:9266697, PubMed:25916169)

The "ST3GAL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ST3GAL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets